Palifermin for patients with haematological malignancies: shifting nursing practice from symptom relief to prevention of oral mucositis.

@article{Fliedner2007PaliferminFP,
  title={Palifermin for patients with haematological malignancies: shifting nursing practice from symptom relief to prevention of oral mucositis.},
  author={Monica C. Fliedner and Brigitte Baguet and Joachim Blankart and Michelle Davies and E. Henriques and Angela Leather and Ewa Mazur and Katalin Mih{\'a}ly and Liesbet M Peeters and Agnes Radv{\'a}nyin{\'e} and Blanka Sedlackova},
  journal={European journal of oncology nursing : the official journal of European Oncology Nursing Society},
  year={2007},
  volume={11 Suppl 1},
  pages={S19-26}
}
Oral mucositis (OM) is an extremely debilitating side effect of certain high-dose chemotherapy and radiotherapy regimens. It is especially prevalent in patients with haematological malignancies who undergo myeloablative therapy and autologous haematopoietic stem cell transplantation (HSCT). Severe erosion of the lining of the oral cavity can make patients' everyday activities, including eating, drinking, swallowing, and talking, difficult or even impossible. Palifermin (Kepivance) was approved… CONTINUE READING